Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2014; 20(1): 53-63
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.53
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.53
Figure 3 Plasma coagulation inhibitors.
AT III: Antithrombin III; TF: Tissue factor; TFPI: TF pathway inhibitor; PS: Protein S; APC: Activated protein C. ↓: Changes in plasma coagulation inhibitors, in patients with inflammatory bowel diseases.
- Citation: Owczarek D, Cibor D, Głowacki MK, Rodacki T, Mach T. Inflammatory bowel disease: Epidemiology, pathology and risk factors for hypercoagulability. World J Gastroenterol 2014; 20(1): 53-63
- URL: https://www.wjgnet.com/1007-9327/full/v20/i1/53.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i1.53